Search

everythinglearnresearchcommunity

for

Search:↓

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

Targeted immunotherapy could be a promising new treatment for hair regrowth.

DM and AA may share a common cause.

Stress hormones and autoimmune reactions can cause hair loss.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

T-cell patterns in skin help distinguish alopecia areata from androgenetic alopecia.

The 3D skin model mimics pemphigus vulgaris and helps test treatments.

New imaging technology can show up to 40 different markers in hair loss tissue, helping to understand hair disease better.

Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.

A specific group of slow-growing stem cells marked by Thy1 is crucial for skin maintenance and healing in mice.

Nonsegmental vitiligo is caused by the immune system attacking skin cells, often linked to other autoimmune diseases.

Selective breeding can enhance immunity in dairy cattle.

Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.

Booster doses of Covaxin improve protection against the Omicron variant.

Inflammation in psoriasis may trigger antimicrobial peptides and cell death.

A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.

Certain substances can help skin cells become anti-inflammatory, aiding in tissue repair.

Higher CRHR1 levels in AA patients lead to increased inflammation.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.

Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

UV light helped human hair transplants survive in mice without broad immunosuppression.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

Ostrich antibodies are a promising, cost-effective treatment for various skin diseases and conditions.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.